Last updated: 2026-09-16 10:32:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Geron Corp. (GERN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.31, with a market capitalisation of $880.19M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.04 to $2.01. This page covers its latest market performance, valuation, price trends and company information.
$880.19M | |
$1.31 | |
$16.80 | |
$0.75 | |
$1.31 | |
158.00 | |
11.41M | |
-- | |
$2.01 | |
$1.04 | |
-- | |
-- |
Geron Corp. (GERN) is trading at $1.31 in pre-market trading as of 2026-09-16 10:10:00, down 0.38% ($0.01) from the previous close of $1.31
Pre-market trading shows how investors are pricing GERN before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Geron Corp. (GERN) moved from $1.57 to $1.31, representing a decline of 16.88% ($0.27).
The stock traded between $1.30 and $1.59 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 10.74 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 27.3%
GERN is currently trading at $1.31, placing it 27.3% of the way from its 52-week low of $1.04 to its 52-week high of $2.01. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 258 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Geron Corp. (GERN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.